Siles Alvarado and Schuler et al. examine the long-term dynamics of SARS-CoV-2 antibodies in individuals with varying COVID-19 severities over 12 months. While anti-N antibodies decline ...

Cutting-edge bispecific and tri-specific antibody therapies headline Innovent’s research portfolio. SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" ...

For hematologic cancers, the past decade was marked by the rise of alternative immunotherapies such as antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric ...

CRP binds to the antibody forming a CRP-antibody complex, which precipitates. Negative: Absence of agglutination indicates a concentration of CRP <6 mg/L or <10 mg/L Semiquantitative An ...

Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint ...

Full results from the trial evaluating Akeso’s first-in-class PD-1/VEGF bispecific antibody are expected to be presented later this year at a medical conference. 1 "The interim analysis results from ...

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc.

Molecular parameters governing antibody FcγR signaling and effector functions in the context of HIV envelope. Cell Reports , 2025; 44 (4): 115331 DOI: 10.1016/j.celrep.2025.115331 Cite This Page : ...